Andrew McPartlin

Andrew McPartlin

Auto-generated profile, based on publicly available information

Andrew McPartlin

Radiation Medicine Program, Princess Margaret Cancer Centre, Toronto, Ontario, Canada; Department of Radiation Oncology, University of Toronto, Toronto, Ontario, Canada

Research Focus & Metrics

Academic Career Length

14Years (2013-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 September 2017 in Practical Radiation Oncology
Verified
Journal Article
Closed access
Aisling BarryAisling Barry
Aisling Barry
AMAndrew McPartlin
Andrew McPartlin
PLPatricia Lindsay
Patricia Lindsay
LWLisa Wang
Lisa Wang
JBJames Brierley
James Brierley
LDLaura A. Dawson
Laura A. Dawson

9 August 2024 in Clinical Cancer Research
Verified
Journal Article
Open access
PDF file
MDMichael J. Dubec
Michael J. Dubec
JPJames Price
James Price
MBMichael Berks
Michael Berks
JGJohn Gaffney
John Gaffney
RLRoss A. Little
Ross A. Little
James P B O'ConnorJames P B O'Connor
James P B O'Connor
Purpose: Hypoxia mediates treatment resistance in solid tumors. We evaluated if oxygen-enhanced MRI–derived hypoxic volume (HVMRI) is repeatable and can detect radiotherapy-induced hypoxia modification in human papillomavirus–associated oropharyngeal head and neck squamous cell cancer. Experimental Design: A total of 27 patients were recruited prospectively between March 2021 and January 2024. HVMRI was measured in primary and nodal tumors prior to standard-of-care (chemo)radiotherapy and then at weeks 2 and 4 (W2 and W4) into therapy. Two pretreatment scans assessed biomarker within-subject coefficient of variation and repeatability coefficient (RC). Cohort treatment response was measured using mixed-effects modeling. Responding lesions were identified by comparing HVMRI change with RC limits of agreement. Results: Oxygen-enhanced MRI identified hypoxia in all lesions. The HVMRI within-subject coefficient of variation was 24.6%, and RC limits of agreement were −45.7% to 84.1%. A cohort median pretreatment HVMRI of 11.3 cm3 reduced to 6.9 cm3 at W2 and 5.9 cm3 at W4 (both P < 0.001). HVMRI was reduced in 54.5% of individual lesions by W2 and in 88.2% by W4. All lesions with W2 hypoxia reduction showed persistent modification at W4. HVMRI reduced in some lesions that showed no overall volume change. Hypoxia modification was discordant between primary and nodal tumors in 50.0% of patients. Conclusions: Radiation-induced hypoxia modification can occur as early as W2, but onset varies between patients and was not necessarily associated with overall size change. Half of all patients had discordant changes in primary and nodal tumors. These findings have implications for patient selection and timing of dose de-escalation strategies in human papillomavirus–associated oropharyngeal carcinoma. See related commentary by Mason, p. 5503

15 May 2023 in Technical Innovations & Patient Support in Radiation Oncology
Verified
Journal Article
Open access
WLWinnie Li
Winnie Li
JPJerusha Padayachee
Jerusha Padayachee
ININMACULADA NAVARRO-DOMENECH
INMACULADA NAVARRO-DOMENECH
JWJeff Winter
Jeff Winter
JDJennifer Dang
Jennifer Dang
PCPeter Chung
Peter Chung
To develop a practice-based training strategy to transition from radiation oncologist to therapist-driven prostate MR-Linac adaptive radiotherapy. In phase 1, 7 therapists independently contoured the prostate and organs-at-risk on T2-weighted MR images from 11 previously treated MR-Linac prostate patients. Contours were evaluated quantitatively (i.e. Dice similarity coefficient [DSC] calculated against oncologist generated online contours) and qualitatively (i.e. oncologist using a 5-point Likert scale; a score ≥ 4 was deemed a pass, a 90% pass rate was required to proceed to the next phase). Phase 2 consisted of supervised online workflow with therapists required no intervention from the oncologist on 10 total cases to advance. Phase 3 involved unsupervised therapist-driven workflow, with offline support from oncologists prior to the next fraction. In phase 1, the mean DSC was 0.92 (range 0.85–0.97), and mean Likert score was 3.7 for the prostate. Five therapists did not attain a pass rate (3–5 cases with prostate contour score < 4), underwent follow-up one-on-one review, and performed contours on a further training set (n = 5). Each participant completed a median of 12 (range 10–13) cases in phase 2; of 82 cases, minor direction were required from the oncologist on 5 regarding target contouring. Radiation oncologists reviewed 179 treatment fractions in phase 3, and deemed 5 cases acceptable but with suggestions for next fraction; all other cases were accepted without suggestions. A training stepwise program was developed and successfully implemented to enable a therapist-driven workflow for online prostate MR-Linac adaptive radiotherapy.

21 November 2022 in Clinical and Translational Radiation Oncology
Verified
Journal Article
Open access
DTDavid J. J Thomson
David J. J Thomson
CCClare Cruickshank
Clare Cruickshank
HBHelen Baines
Helen Baines
RBRussell Banner
Russell Banner
MBMatthew Beasley
Matthew Beasley
EHEmma Hall
Emma Hall
• There is a lack of prospective level I evidence for the use of PBT for most adult cancers including oropharyngeal squamous cell carcinoma (OPSCC). • TORPEdO is the UK’s first PBT clinical trial and aims to determine the benefits of PBT for OPSCC. • Training and support has been provided before and during the trial to reduce variations of contouring and radiotherapy planning. • There is a strong translational component within TORPEdO. Imaging and physics data along with blood, tissue collection will inform future studies in refining patient selection for IMPT.

13 September 2023 in medRxiv
Verified
Preprint
Open access
PDF file
EWErin E Watson
Erin E Watson
KHKatrina Hueniken
Katrina Hueniken
JLJunhyung Lee
Junhyung Lee
SHSophie H. Huang
Sophie H. Huang
AAAmr El Maghrabi A
Amr El Maghrabi A
AHAli A Hosni
Ali A Hosni
Purpose: Osteoradionecrosis of the jaw (ORN) can manifest in varying severity. The aim of this study is to identify ORN risk factors and develop a novel classification to depict the severity of ORN. Methods: Consecutive head-and-neck cancer (HNC) patients treated with curative-intent IMRT (≥45Gy) in 2011-2018 were included. Occurrence of ORN was identified from in-house prospective dental and clinical databases and charts. Multivariable logistic regression model was used to identify risk factors and stratify patients into high-risk and low-risk groups. A novel ORN classification system was developed to depict ORN severity by modifying existing systems and incorporating expert opinion. The performance of the novel system was compared to fifteen existing systems for their ability to identify and predict serious ORN event (jaw fracture or requiring jaw resection). Results: ORN was identified in 219 out of 2732 (8%) consecutive HNC patients. Factors associated with high-risk of ORN were: oral-cavity or oropharyngeal primaries, received IMRT dose ≥60Gy, current/ex-smokers, and/or stage III-IV periodontal disease. The ORN rate for high-risk vs low-risk patients was 12.7% vs 3.1% (p<0.001) with an area-under-the-receiver-operating-curve (AUC) of 0.71. Existing ORN systems overclassified serious ORN events and failed to recognize maxillary ORN. A novel ORN classification system, RadORN, was proposed based on vertical extent of bone necrosis and presence/absence of exposed bone/fistula. This system detected serious ORN events in 5.7% of patients and statistically outperformed existing systems. Conclusion: We identified risk factors for ORN, and proposed a novel ORN classification system based on vertical extent of bone necrosis and presence/absence of exposed bone/fistula. It outperformed existing systems in depicting the seriousness of ORN, and may facilitate clinical care and clinical trials.

6 May 2013 in Lung Cancer
Verified
Journal Article
Closed access
PDF file
AMA.J. McPartlin
A.J. McPartlin
SCS. Chaudhry
S. Chaudhry
RSR. Swindell
R. Swindell
NBN. Bayman
N. Bayman
PBP. Burt
P. Burt
LPL. Pemberton
L. Pemberton